This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to advance the development of prognostic and monitoring biomarkers for neutrophil-driven secondary brain injury in patients with spontaneous intracerebral hemorrhage (SICH). The $704,313 award to Trustees of Boston University Medical Campus will fund a 2-year research project to define and validate a standardized protocol for detecting a specific neutrophil biomarker, DESPR+[N], that has shown potential to prognosticate SICH patient outcomes and monitor ongoing neuroinflammation. The research will focus on optimizing flow cytometry detection of this biomarker in a diverse SICH patient cohort, and validating the cytometry results against quantitative immunofluorescence. If successful, this work could advance the use of this neutrophil biomarker to better stratify SICH patients in clinical trials and monitor treatment effects targeting neuroinflammatory processes.
Generated 3/25/25, 1:45 AM